Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis

Mayo, Skye C.; Jong, Mechteld C. de; Bloomston, Mark; Pulitano, Carlo; Clary, Bryan M.; Reddy, Srinevas K.; Gamblin, T. Clark; Celinski, Scott; Kooby, David A.; Staley, Charles A.; Stokes, Joseph; Chu, Carrie K.; Arrese, David; Ferrero, Alessandro; Schulick, Richard D.; Choti, Michael A.; Geschwind, Jean François H.; Strub, Jennifer; Bauer, Todd W.; Adams, Reid B.; Aldrighetti, Luca; Mentha, Gilles; Capussotti, Lorenzo; Pawlik, Timothy M.

doi:10.1245/s10434-011-1832-y

Cited by 156 publications

(118 citation statements)

References 31 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…There is no high-quality evidence to demonstrate superiority of either approach. When there is a high disease volume in liver, surgical resection is less beneficial [99] and transarterial embolization is preferred. Hepatic transarterial embolization, chemoembolization, or radioembolization (TARE) with Yttrium-90 are commonly used.…”

Section: • Local Ablative Therapymentioning

confidence: 99%

Recent Advances in the Management of Endocrine Malignancies Associated with Hereditary Hyperparathyroidism Syndromes

Li¹,

Simonds

2017

Int. J. Endo. Oncol.

View full text Add to dashboard Cite

Hereditary hyperparathyroidism syndromes, such as multiple endocrine neoplasm type 1, type 2A and the hyperparathyroidism-jaw tumor syndrome, are associated with an increased incidence of malignancies involving the neuroendocrine tissue of the pancreas and thymus, parathyroid and thyroid glands. The natural history of these endocrine tumors can differ from nonhereditary malignancies. The surgical approach, the only potentially curative treatment option for these endocrine malignancies, has evolved considerably in recent years. Newer targeted therapies, such as small molecule kinase inhibitors, somatostatin analogs and peptide receptor radionuclide therapy, are being developed. We provide here a comprehensive review of the current standards of treatment and emerging novel therapies for the endocrine malignancies commonly associated with hereditary hyperparathyroidism syndromes.

show abstract

Section: • Local Ablative Therapymentioning

confidence: 99%

Recent Advances in the Management of Endocrine Malignancies Associated with Hereditary Hyperparathyroidism Syndromes

Li¹,

Simonds

2017

Int. J. Endo. Oncol.

View full text Add to dashboard Cite

show abstract

“…For example, for many patients, the change in their management plan was a result of the presence at the mdlc of providers with significant expertise in chemotherapy and intraarterial therapy [35][36][37][38] . For patients who had seen only an outside surgical provider, the change in the treatment recommendations might partly have arisen from a lack of sufficient expertise among the outside providers with respect to the administration of chemotherapy and intraarterial therapy for hepatobiliary tumours.…”

Section: (E)mentioning

confidence: 99%

Impact of a Single-Day Multidisciplinary Clinic on the Management of Patients with Liver Tumours

et al. 2013

View full text Add to dashboard Cite

51%) returned for a follow-up, and 154 of the returnees (89%) received treatment, primarily intraarterial therapy (n = 88, 57%), systemic chemotherapy (n = 60, 39%), or liver resection (n = 32, 21%). Enrollment in a clinical trial was proposed to 34 patients (10%), and 21 of the 34 (62%) were accrued. ConclusionsPatient assessment by our multidisciplinary liver clinic had a significant impact on management, resulting in alterations to imaging and pathology interpretation, diagnosis, and management plan. The mdlc is an effective and convenient means of delivering expert opinion about the diagnosis and management of liver tumours.

show abstract

“…Resection alone is supported by favourable long-term outcomes in large retrospective trials [11]. However, complete surgical resection is only possible in a subset of people with NLMs due to excessive metastatic burden and anatomical location [1,11].…”

Section: Introductionmentioning

confidence: 99%

An Overview of the Surgical Management of Hepatic Neuroendocrine Metastases

Pathak

Dash

Taylor

et al. 2012

Indian J Surg Oncol

View full text Add to dashboard Cite

Neuroendocrine tumours (NET) frequently metastasise to the liver (NLM) and are associated with significant morbidity and mortality. Numerous treatment options have been implemented both for cure, and to implement disease control. Surgical treatment includes curative resection, palliative cytoreductive resection and transplantation. Complete surgical resection is only possible in a subset of people with NLMs due to excessive metastatic burden and anatomical location. Ablative therapies may be used either as an adjunct to surgery or as a primary treatment. The purpose of the following article is to summarise surgical treatment strategies in the management of patients with hepatic neuroendocrine metastases, based on the available literature.

show abstract

Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis

Cited by 156 publications

References 31 publications

Recent Advances in the Management of Endocrine Malignancies Associated with Hereditary Hyperparathyroidism Syndromes

Recent Advances in the Management of Endocrine Malignancies Associated with Hereditary Hyperparathyroidism Syndromes

Impact of a Single-Day Multidisciplinary Clinic on the Management of Patients with Liver Tumours

An Overview of the Surgical Management of Hepatic Neuroendocrine Metastases

Contact Info

Product

Resources

About